Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
24.17
-1.33 (-5.22%)
At close: Nov 16, 2026, 4:00 PM EST
24.22
+0.05 (0.21%)
After-hours: Nov 16, 2026, 7:30 PM EST
Tango Therapeutics Employees
Tango Therapeutics had 137 employees as of December 31, 2025. The number of employees decreased by 18 or 11.61% compared to the previous year. That makes Tango Therapeutics the 29,486th largest employer in the world and 3,726th in the United States.
Employees
137
Change (1Y)
-18
Growth (1Y)
-11.61%
Revenue / Employee
n/a
Profits / Employee
-$1,518,234
Market Cap
4.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 137 | -18 | -11.61% |
| Dec 31, 2024 | 155 | 15 | 10.71% |
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Sep 30, 2022 | 109 | 26 | 31.33% |
| Jun 30, 2022 | 103 | 17 | 19.77% |
| Mar 31, 2022 | 98 | 21 | 27.27% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Sep 30, 2021 | 83 | 6 | 7.79% |
| Jun 30, 2021 | 86 | - | - |
| Mar 31, 2021 | 77 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| AbCellera Biologics | 562 |
| Travere Therapeutics | 497 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Tarsus Pharmaceuticals | 370 |
| Cogent Biosciences | 258 |
| Relay Therapeutics | 218 |
TNGX News
- 6 days ago - Tango Therapeutics price target lowered to $67 from $68 at H.C. Wainwright - TheFly
- 6 days ago - Tango Therapeutics price target raised to $47 from $46 at JPMorgan - TheFly
- 6 days ago - Tango Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Tango Therapeutics reports Q3 EPS (39c), consensus (35c) - TheFly
- 7 days ago - Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights - GlobeNewsWire
- 7 days ago - Tango Therapeutics Quarterly report: Q3 2026 - Filings
- 7 days ago - Tango Therapeutics Earnings release: Q3 2026 - Filings
- 12 days ago - Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study - TheFly